HBV相关肝细胞癌患者抗病毒药物的选择

冯明洋; 王晖

doi:10.3969/j.issn.1001-5256.2022.11.004

HBV相关肝细胞癌患者抗病毒药物的选择

DOI: 10.3969/j.issn.1001-5256.2022.11.004

冯明洋,
王晖^, ,

上海交通大学医学院附属瑞金医院感染科，上海 200025

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：冯明洋负责查找文献、分析资料、撰写文章；王晖负责确定写作思路、指导文章撰写及最后定稿。

详细信息

通信作者:
王晖，wanghuirj@163.com

计量
- 文章访问数: 730
- HTML全文浏览量: 155
- PDF下载量: 116
- 被引次数: 0
出版历程
- 收稿日期: 2022-09-21
- 录用日期: 2022-10-21
- 出版日期: 2022-11-20

Selection of antiviral drugs for patients with hepatitis B virus-associated hepatocellular carcinoma

Mingyang FENG,
Hui WANG^{,
,}

Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

More Information

Corresponding author: WANG Hui, wanghuirj@163.com(ORCID: 0000-0002-1440-8942)

摘要

摘要: HBV感染是肝细胞癌(HCC)发生和发展的主要危险因素，通过诱导肝纤维化、遗传和表观遗传改变以及活性病毒编码蛋白的表达来促进HCC的进展。多项研究证实病毒状态影响HCC预后，有效的抗病毒治疗有助于预防或延迟HBV相关HCC复发，提高患者接受根治性或系统性治疗后的总生存期，改善综合治疗预后。因此，正确选择抗病毒药物对于HBV相关HCC患者的抗病毒治疗至关重要。本文就HBV相关HCC患者抗病毒药物的选择进行简要综述，以供临床参考。
- 乙型肝炎病毒 /
- 癌，肝细胞 /
- HBV再激活 /
- 抗病毒药
Abstract: Hepatitis B virus (HBV) infection is a key risk factor for the development and progression of hepatocellular carcinoma (HCC) and it promotes the progression of HCC by inducing liver fibrosis, genetic and epigenetic alterations, and the expression of active virally encoded proteins. Many studies have confirmed the influence of viral status on the prognosis of HCC, and effective antiviral therapy can help prevent or delay the recurrence of HBV-associated HCC, increase the overall survival time of patients undergoing radical or systemic, and improve the prognosis after multimodality therapy. Therefore, correct selection of antiviral drugs is crucial for the antiviral treatment of patients with HBV-associated HCC. This article briefly reviews the selection of antiviral drugs for patients with HBV-associated HCC, so as to provide a reference for clinical practice.
- Hepatitis B Virus /
- Carcinoma, Hepatocellular /
- HBV Reactivation /
- Antiviral Agents

HTML全文

参考文献(43)

[1]	VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263.
[2]	LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
[3]	ROBERTS SK, MAJEED A, KEMP W. Controversies in the management of hepatitis B: hepatocellular carcinoma[J]. Clin Liver Dis, 2021, 25(4): 785-803. DOI: 10.1016/j.cld.2021.06.006.
[4]	HUNG IF, POON RT, LAI CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection[J]. Am J Gastroenterol, 2008, 103(7): 1663-1673. DOI: 10.1111/j.1572-0241.2008.01872.x.
[5]	XIA Z, HE L, XIONG L, et al. The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments: A network meta-analysis[J]. Medicine (Baltimore), 2020, 99(33): e20877. DOI: 10.1097/MD.0000000000020877.
[6]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[7]	Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: A 2021 update[J]. J Clin Hepatol, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008. 中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J]. 临床肝胆病杂志, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.
[8]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[9]	ARZUMANYAN A, REIS HM, FEITELSON MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma[J]. Nat Rev Cancer, 2013, 13(2): 123-135. DOI: 10.1038/nrc3449.
[10]	SARTORIUS K, AN P, WINKLER C, et al. The epigenetic modulation of cancer and immune pathways in hepatitis B virus-associated hepatocellular carcinoma: the influence of HBx and miRNA dysregulation[J]. Front Immunol, 2021, 12: 661204. DOI: 10.3389/fimmu.2021.661204.
[11]	PENG XF, HUANG SF, CHEN LJ, et al. Targeting epigenetics and lncRNAs in liver disease: From mechanisms to therapeutics[J]. Pharmacol Res, 2021, 172: 105846. DOI: 10.1016/j.phrs.2021.105846.
[12]	CHEN L, HUANG W, WANG L, et al. The effects of epigenetic modification on the occurrence and progression of liver diseases and the involved mechanism[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(4): 259-270. DOI: 10.1080/17474124.2020.1736042.
[13]	VEZZANI B, CARINCI M, PREVIATI M, et al. Epigenetic regulation: A link between inflammation and carcinogenesis[J]. Cancers (Basel), 2022, 14(5): 1221. DOI: 10.3390/cancers14051221.
[14]	SUN X, YAN X, SHAO R, et al. Efficacy of antiviral therapy in patients with hepatitis B-related primary liver cancer[J]. J BUON, 2021, 26(3): 897-903.
[15]	WU CY, CHEN YJ, HO HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection[J]. JAMA, 2012, 308(18): 1906-1914. DOI: 10.1001/2012.jama.11975.
[16]	WANG Y, XIANG X, CHEN L, et al. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy[J]. Oncotarget, 2016, 7(36): 58553-58562. DOI: 10.18632/oncotarget.10155.
[17]	WONG JS, WONG GL, TSOI KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2011, 33(10): 1104-1112. DOI: 10.1111/j.1365-2036.2011.04634.x.
[18]	YIN J, LI N, HAN Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study[J]. J Clin Oncol, 2013, 31(29): 3647-3655. DOI: 10.1200/JCO.2012.48.5896.
[19]	QI W, SHEN J, DAI J, et al. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study[J]. Cancer Med, 2021, 10(23): 8421-8431. DOI: 10.1002/cam4.4348.
[20]	ZHANG X, LI C, WEN T, et al. The different effects of nucleotide and nucleoside analogues on the prognosis of HBV-related HCC after curative resection[J]. J Gastrointest Surg, 2021, 25(6): 1419-1429. DOI: 10.1007/s11605-020-04633-3.
[21]	GUAN RY, SUN BY, WANG ZT, et al. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma[J]. Am J Surg, 2022, 224(1 Pt B): 494-500. DOI: 10.1016/j.amjsurg.2022.01.008.
[22]	HUANG G, LAU WY, WANG ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial[J]. Ann Surg, 2015, 261(1): 56-66. DOI: 10.1097/SLA.0000000000000858.
[23]	LEE TY, LIN JT, ZENG YS, et al. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation[J]. Hepatology, 2016, 63(5): 1517-1527. DOI: 10.1002/hep.28266.
[24]	CHO H, AHN H, LEE DH, et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals[J]. J Viral Hepat, 2018, 25(6): 707-717. DOI: 10.1111/jvh.12855.
[25]	KIM JH, SINN DH, KIM K, et al. Lamivudine versus entecavir for newly diagnosed hepatitis B virus-related hepatocellular carcinoma[J]. Gut Liver, 2016, 10(6): 939-947. DOI: 10.5009/gnl15527.
[26]	CHOI J, JO C, LIM YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection[J]. Hepatology, 2021, 73(2): 661-673. DOI: 10.1002/hep.31289.
[27]	SHEN J, QI W, DAI J, et al. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy[J]. Chin Med J (Engl), 2021, 135(3): 301-308. DOI: 10.1097/CM9.0000000000001864.
[28]	GE Z, MA J, QIAO B, et al. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality[J]. Medicine (Baltimore), 2020, 99(32): e21454. DOI: 10.1097/MD.0000000000021454.
[29]	TSAI MC, WANG CC, LEE WC, et al. Tenofovir is superior to entecavir on tertiary prevention for BCLC stage 0/A hepatocellular carcinoma after curative resection[J]. Liver Cancer, 2021, 11(1): 22-37. DOI: 10.1159/000518940.
[30]	LEE JH, KIM BK, PARK SY, et al. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma[J]. Eur J Intern Med, 2021, 89: 48-55. DOI: 10.1016/j.ejim.2021.02.019.
[31]	WANG XH, HU ZL, FU YZ, et al. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection[J]. J Gastroenterol, 2022, 57(3): 185-198. DOI: 10.1007/s00535-022-01855-x.
[32]	MURATA K, TSUKUDA S, SUIZU F, et al. Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection[J]. Hepatology, 2020, 71(5): 1533-1545. DOI: 10.1002/hep.30956.
[33]	ZHANG Y, LI X, ZHANG Y, et al. Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155[J]. Ann Hepatol, 2019, 18(3): 494-500. DOI: 10.1016/j.aohep.2018.11.007.
[34]	ARAKAWA Y, SHIMADA M, UTSUNOMIYA T, et al. Effects of pegylated interferon α 2b on metastasis of hepatocellular carcinoma[J]. J Surg Res, 2012, 172(1): 95-101. DOI: 10.1016/j.jss.2010.07.023.
[35]	XU J, LI J, CHEN J, et al. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis[J]. Adv Clin Exp Med, 2015, 24(2): 331-340. DOI: 10.17219/acem/29760.
[36]	YANG S, LIN Q, LIN W, et al. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review[J]. World J Surg Oncol, 2016, 14(1): 159. DOI: 10.1186/s12957-016-0912-7.
[37]	ZUO CH, XIA M, LIU JS, et al. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection[J]. Asian Pac J Cancer Prev, 2015, 16(1): 245-251. DOI: 10.7314/apjcp.2015.16.1.245.
[38]	WU J, YIN Z, CAO L, et al. Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis[J]. Medicine (Baltimore), 2018, 97(28): e11295. DOI: 10.1097/MD.0000000000011295.
[39]	HU B, YU M, MA X, et al. IFNα potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment[J]. Cancer Discov, 2022, 12(7): 1718-1741. DOI: 10.1158/2159-8290.CD-21-1022.
[40]	ZHU Y, CHEN M, XU D, et al. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma[J]. Cell Mol Immunol, 2022, 19(6): 726-737. DOI: 10.1038/s41423-022-00848-3.
[41]	QU LS, JIN F, HUANG XW, et al. Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma[J]. J Surg Oncol, 2010, 102(7): 796-801. DOI: 10.1002/jso.21741.
[42]	QI W, ZHANG Q, XU Y, et al. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation[J]. J Viral Hepat, 2020, 27(4): 387-396. DOI: 10.1111/jvh.13236.
[43]	QI WQ, ZHANG Q, WANG X, et al. Long-term clinical benefit of Peg-IFNα and NAs sequential anti-viral therapy on HBV related HCC[J]. Neoplasma, 2021, 68(1): 200-207. DOI: 10.4149/neo_2020_200506N493.